DPLife OD is not only known for its efficacy but also for its safety during pregnancy. It has been categorized as Category A by the US FDA, reflecting its suitability for use in pregnant individuals. DPLife OD offers a comprehensive solution for managing morning sickness during pregnancy, providing relief through a combination of doxylamine succinate and pyridoxine hydrochloride, whose specific actions complement each other to address the underlying causes of nausea and vomiting. The unique formulation is optimized for maximum effectiveness, especially in the mornings when nausea tends to be more pronounced.
Mode Of Action:
The exact mechanism of action for the combination is not known. However, it is understood that the chemoreceptor trigger zone is stimulated by neurotransmitters such as dopamine, histamine, and serotonin, leading to the activation of the vomiting center, causing nausea and vomiting
Doxylamine Succinate Effectively blocks the Chemoreceptor Trigger Zone, inhibiting the binding of neurotransmitters and controlling nausea.
Pyridoxine HydrochlorideIt has been shown to reduce pregnancy-related nausea in many studies. It is absorbed mainly from the jejunum (small intestine), and the enteric-coated tablets are used for this reason. Peak plasma concentrations, after using delayed-release preparations, occur around 4-7 hours, which is why the drug is recommended at bedtime. Doxylamine is metabolized in the liver, and the metabolites are excreted through the kidneys.
Salient Features:
- Enteric coated tablets
- Drug release begins in the intestines only
- Gradual release for optimal absorption
- Adequate blood levels by early morning
- Hence, adequate protection against NVP, when patients needs it most
Indications:
Dosage:
1 Tablet OD, at Bedtime
Instructions for usage:
- As directed by the health care provider
STORAGE:
- Store in cool, dry & dark place.
- Keep out of reach of children.
Contraindications:
Not recommended for use in women with a confirmed hypersensitivity to doxylamine succinate, pyridoxine hydrochloride, or any inactive ingredient present in the formulation.
Additionally, the use of monoamine oxidase (MAO) inhibitors can enhance and prolong the adverse central nervous system effects and drying effects on the anticholinergic pathway of antihistamines.
FAQ’s:
DPLife OD is not recommended for individuals with confirmed hypersensitivity to doxylamine succinate, pyridoxine hydrochloride, or any inactive ingredient in the formulation. Additionally, it should not be used with monoamine oxidase (MAO) inhibitors due to potential adverse effects.
DPLife OD should be used as directed by the healthcare provider. It should be stored in a cool, dry, and dark place, and kept out of reach of children.
The recommended dosage is 1 tablet OD (once daily) at bedtime.
DPLife OD is formulated for delayed release, with peak plasma concentrations occurring 4-7 hours after use. This optimizes effectiveness in the morning when nausea is pronounced, providing adequate protection against nausea and vomiting of pregnancy (NVP).
